報價延遲最少15分鐘:2026/01/08 16:13 EST
盤後時段
|
||||
|
4.64 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.64
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.99/-0.76
|
|
企業價值
306.25M
|
| 資產負債 |
|
每股賬面淨值
1.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
5.72M
|
|
每股收益
0.01
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325,which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD. |
